November 28th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Comparative Efficacy, Tolerability With RP2D of Belzutifan in LITESPARK-013 Trial for ccRCC
November 11th 2023Results unveiled at the 2023 International Kidney Cancer Symposium revealed that patients with advanced clear cell renal cell carcinoma in the 200-mg dose group achieved an overall response rate of 23.1% based on blinded independent central review.
Read More
Evaluating Belzutifan Its Approval for Cancers Associated With VHL Disease
November 11th 2023In a presentation at the 2023 International Kidney Cancer Symposium, Jaleh Fallah, MD, discussed the regulatory agency’s evaluation of data from the phase 2 LITESPARK-004 trial, which led to the approval of belzutifan.
Read More
Novel TKI Zanzalintinib Confers Promising Antitumor Activity in Advanced ccRCC
November 10th 2023Patients with advanced clear cell renal cell carcinoma treated with zanzalintinib had experienced promising antitumor activity with manageable toxicity regardless of prior treatment with cabozantinib.
Read More
Novel Therapeutic Targets Represent Unmet Need in Translocation RCC
November 10th 2023An expert discussed how recent studies in patients with translocation RCC, a rare type of RCC, have demonstrated that the disease responds well to immune checkpoint inhibitors, but more focus is needed on novel targets to treat it.
Read More
Roundtable Roundup: Motzer and Ornstein Survey Participants on Frontline RCC Therapy
November 4th 2023In separate, live virtual events, Robert J. Motzer, MD; and Moshe Ornstein, MD, MA, discussed the case of a patient with metastatic clear cell renal cell carcinoma (RCC) and options for therapy.
Read More
Treatment Selection and Dosing Strategies Based on Trial Data in RCC
November 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, and participants discussed their takeaways from the phase 3 trials of immunotherapy and tyrosine kinase inhibitors in frontline renal cell carcinoma. This is the second article based on this event.
Read More
Sequencing Choices from First- to Third-Line Regimens in ccRCC
October 25th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, asked participants about what sequence of therapies they would use in the first, second, and third lines for a patient with metastatic clear cell renal cell carcinoma. This is the first of 2 articles based on this event.
Read More
Immunotherapy Plus TKI Yields Impressive Results for Subgroups With Advanced RCC
October 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel George, MD, discussed the CheckMate 9ER trial in terms of bone, liver, and lung metastases and other subgroups in patients with advanced clear cell renal cell carcinoma.
Read More
Considering Disease Risk Criteria When Choosing Systemic Therapy for Advanced RCC
September 29th 2023Combination therapies for patients with advanced renal cell carcinoma provides clinicians with new treatment avenues for their patients. To assess which path to go down, Tian Zhang, MD, MHS, and Randy F. Sweis, MD, led virtual discussions on evaluating patients’ risk criteria to determine their proper treatment.
Read More
Nivolumab plus Cabozantinib Continues to Show Benefit in Advanced RCC
September 5th 2023In the second article of a 2-part series, Rana McKay, MD, discussed follow-up analyses of the phase 3 CheckMate 9ER trial that showed the benefit of nivolumab plus cabozantinib vs sunitinib for patients with advanced renal cell carcinoma.
Read More
Liu Discusses Frontline Treatment and Adverse Event Management in ccRCC
August 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sandy Liu, MD, discussed the frontline tyrosine kinase inhibitor/immune checkpoint inhibitor regimens and how to manage toxicities related to these regimens.
Read More
Activity Observed With Cabozantinib/Nivolumab/Ipilimumab in RCCvh
August 21st 2023In an interview with Targeted Oncology, Bradley A. McGregor, MD, discussed the main takeaways from a phase 3 study of cabozantinib, nivolumab, and ipilimumab for patients with renal cell carcinoma with variant histologies.
Read More